What is a concise overview of the treatment and management of severe asymmetrical septal hypertrophy?

Severe Asymmetrical Septal Hypertrophy: Treatment and Management Overview

For patients with severe asymmetrical septal hypertrophy causing drug-refractory symptoms and left ventricular outflow tract obstruction (LVOTO), surgical septal myectomy performed at experienced HCM centers is the first-line invasive treatment, with alcohol septal ablation reserved for those with surgical contraindications or unacceptable surgical risk. 1, 2, 3

Initial Medical Management

Beta-blockers or verapamil are first-line medical therapy for symptomatic patients with obstructive HCM. 1, 4 These negative inotropic agents reduce contractility and improve diastolic filling, thereby reducing LVOT gradients and relieving symptoms of dyspnea and chest pain.

Medical Therapy Considerations:

• Mavacamten (cardiac myosin inhibitor) is now FDA-approved for symptomatic obstructive HCM when first-line therapy provides inadequate relief 2
• Disopyramide can be added to beta-blockers or verapamil for additional negative inotropic effect 1
• Diuretics may be cautiously added when congestive symptoms persist despite optimal therapy 1

Critical Medications to AVOID:

• Nifedipine and other dihydropyridine calcium channel blockers are potentially harmful in obstructive HCM 1, 4
• Digitalis is potentially harmful for dyspnea treatment in HCM without atrial fibrillation 1, 4
• Intravenous positive inotropes (dopamine, dobutamine, norepinephrine) are potentially harmful for acute hypotension in obstructive HCM 1, 4
• ACE inhibitors/ARBs should be used cautiously or avoided in patients with resting or provocable LVOT obstruction 4, 1

Septal Reduction Therapy (SRT) Indications

SRT should ONLY be performed when ALL three criteria are met: 1, 4, 1, 3

1. Clinical Criteria:

• Severe dyspnea or chest pain (NYHA class III or IV)
• Occasionally syncope or near-syncope with exertion
• Symptoms interfere with daily activities or quality of life
• Despite optimal medical therapy

2. Hemodynamic Criteria:

• Dynamic LVOT gradient ≥50 mm Hg at rest or with physiologic provocation
• Associated with septal hypertrophy and systolic anterior motion (SAM) of mitral valve

3. Anatomic Criteria:

• Sufficient anterior septal thickness to perform procedure safely in operator's judgment

Surgical Septal Myectomy vs. Alcohol Septal Ablation

Surgical septal myectomy is the preferred first-line invasive treatment for the majority of eligible patients. 1, 4, 3

Surgical Myectomy Advantages:

• Mortality rate <1% at experienced centers 3
• Clinical success rate 90-95% 3
• Effective for broadest range of patients, including those with very thick septum (>30 mm) 3
• Allows gradient relief at any ventricular level 3
• Long-term survival similar to age-matched general population 3
• Lower need for repeat intervention 3
• Superior 10-year survival compared to alcohol ablation 3

Alcohol Septal Ablation Indications:

Reserved for specific situations: 1, 4, 3

• Surgery contraindicated due to serious comorbidities
• Unacceptable surgical risk due to advanced age
• Patient preference after thorough shared decision-making discussion

Alcohol Ablation Limitations:

• Effectiveness uncertain with septal thickness >30 mm 1, 4
• Less effective with gradients ≥100 mm Hg 3
• Higher permanent pacemaker requirement 3
• Greater need for repeat intervention 3
• Lower 10-year survival compared to myectomy 3

Critical Contraindications to SRT

SRT should NOT be performed in: 1, 4

• Asymptomatic patients with normal exercise tolerance
• Patients whose symptoms are controlled on optimal medical therapy
• Outside of comprehensive HCM programs with dedicated multidisciplinary care
• Patients <21 years old for alcohol septal ablation 1
• When concomitant cardiac disease requires surgical correction (alcohol ablation contraindicated; perform myectomy instead) 1, 4

Operator Experience Requirements

"Experienced operators" are defined as: 1, 4, 1

• Individual operator with ≥20 procedures cumulative volume, OR
• Individual operator working in dedicated HCM program with ≥50 procedures cumulative total

Special Populations

Pediatric Patients:

• Surgical myectomy can be beneficial in symptomatic children with severe resting obstruction (>50 mm Hg) when standard medical therapy fails 1, 4, 1
• Alcohol ablation should NOT be performed in patients <21 years old 1

Earlier Intervention Considerations:

Myectomy may be reasonable at NYHA class II (earlier than typical) when: 3

• Severe progressive pulmonary hypertension attributable to LVOTO or mitral regurgitation
• Left atrial enlargement with ≥1 episodes of symptomatic atrial fibrillation
• Poor functional capacity attributable to LVOTO on exercise testing
• Children/young adults with very high resting gradients (>100 mm Hg)

Additional Management Considerations

Atrial Fibrillation:

• Oral anticoagulation (DOACs or warfarin) should be considered default treatment regardless of CHADS2-VASc score 2

Exercise:

• Healthy recreational exercise (light to vigorous intensity) has not been associated with increased ventricular arrhythmia risk 2
• Exercise stress testing helps determine exercise tolerance and latent exercise-provoked LVOTO 2

Sudden Cardiac Death Risk:

• Risk stratification using established markers and individual risk scores facilitates ICD decision-making 2
• Pediatric risk stratification differs from adults and varies with age/body size 2

Key Pitfalls to Avoid

1. Never perform mitral valve replacement solely for LVOTO relief when SRT is an option 1, 4, 3
2. Never use positive inotropes for hypotension in obstructive HCM—they worsen obstruction 1, 4
3. Never perform SRT outside comprehensive HCM centers—outcomes are significantly better at experienced centers 1, 4, 2, 3
4. Consultation with experienced HCM centers is reasonable when discussing treatment options for eligible patients 1, 4